AI assistant
Immunome Inc. — Director's Dealing 2020
Oct 2, 2020
32238_dirs_2020-10-01_a6463c69-e02a-4c06-b29f-ed1bfb869742.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-01
Reporting Person: Morin Michael (Chief Scientific Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $1.80 | 2025-11-15 | Common Stock (3620) | Direct | |
| Employee Stock Option (right to buy) | $0.06 | 2027-03-06 | Common Stock (189972) | Direct | |
| Employee Stock Option (right to buy) | $0.06 | 2027-04-12 | Common Stock (8888) | Direct | |
| Employee Stock Option (right to buy) | $0.54 | 2030-03-02 | Common Stock (60426) | Direct | |
| Employee Stock Option (right to buy) | $2.40 | 2030-08-03 | Common Stock (73472) | Direct | |
| Employee Stock Option (right to buy) | $2.40 | 2030-08-03 | Common Stock (40964) | Direct |
Footnotes
F1: Fully vested.
F2: One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing June 30, 2019, subject to the
Reporting Person continuing to provide service through each such date.
F3: One forty-eighth (1/48th) of the shares subject to the option vested or shall vest each month commencing April 15, 2020, subject to the Reporting Person continuing to provide service through each such date.
F4: The shares subject to the option shall vest on November 1, 2024, subject to the Reporting Person continuing to provide service through each such date.